In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tianjin chosen for China nanotech cancer diagnostics research centre:

This article was originally published in Clinica

Executive Summary

China has launched a research centre specialising in developing nanotech solutions for cancer diagnosis and treatment. The Tianjin-based centre is a joint venture between the Chinese Academy of Sciences, the Institute of High Energy Physics, the National Center for Nanoscience & Technology and the Tianjin Medical University Cancer Institute and Hospital. It will provide an interdisciplinary research platform, for those working on developing nanotech in the field of oncology, according to the Asia-Pacific life sciences business magazine BioSpectrum.

You may also be interested in...



EU Health Program To Help Boost Post-Coronavirus Recovery

The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.

ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval

The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.

Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel